Abstract P1-17-08: Patient preferences: Results of a German adaptive choice-based conjoint analysis study in patients on palliative treatment for advanced breast cancer (aBC)
Authors: Reinisch Mattea , Marschner Norbert , Otto Thorsten , Korfel Agnieszka , Stoffregen Clemens , Wöckel Achim 
Published: March 2020

Objective: This study aimed to identify patient preferences in aBC related to cancer treatment characteristics, i.e. to determine the relevance of gained lifetime (OS) and time to progression (PFS) in relation to quality of life (QoL) and therapy-associated side effects. Methods: Post-menopausal women with HR+/HER2-aBC receiving 1st or 2nd line treatment were recruited throughout Germany. Patient relevant attributes to assess aBC therapies were collected in a stepwise multi-methodological approach, consisting of desk research, qualitative interviews with patients (n=12), caregivers (n=3) and aBC treating physicians (n=2) and iterative reviews of the empirical findings in a cross-functional team. A draft conjoint matrix was developed which was refined by means of two pre-tests with aBC patients (n=9). The final conjoint matrix consisted of two attributes for therapy goals (OS and PFS), four for QoL and six for side effects. It represented the basis of the subsequent quantitative survey using adaptive choice-based conjoint methodology. Results: In the qualitative phase, QoL emerged as a multidimensional concept, consisting of several factors such as ability to lead a ‘normal’ life, physical capability to do things like before, mobility, carefreeness (not continuously be reminded of the disease), having goals and being able to go for them, and spend quality time with family and friends. Factors limiting QoL were symptom burden, medical controls and side effects, which were considered particularly disturbing if long-lasting, affecting everyday life and when effective management was not available. The quantitative sample consisted of 104 patients (67% 50-64 yrs/33% &gt;65 yrs). Time from aBC diagnosis to survey participation was ≤5 years and &gt;5 years in 50% of patients each. At the time of the survey, 67 patients (64.4%) were receiving 1st line and 37 (35.6%) 2nd line treatment, i.e. regular oral intake in 80%, regular injections in 29% and regular infusions in 15% of patients; the start of the current treatment was ≤1 year in 43% and &gt;1 year in 57% of patients. QoL parameters (physical mobility and flexibility) received the highest value (19.4%), followed by treatment goals (OS 15.2%, PFS 14.4%). Therapy-related side effects turned out to be less important overall with nausea/vomiting being the most relevant side effect (9.3%), followed by infection risk (6.4%), diarrhea (2.9%) and mucosal dryness (1.2%). No significant differences were found between 1st and 2nd line patients. A relation between having experienced a side effect in the past and a desire to avoid it was identified for nausea, vomiting, and dry mucosa. There was no relation between the desire to avoid a side effect and its severity in the past. McFadden pseudo R2 (0.805), Root-Likelihood (0.864) and Chi-square test (2809.041, highly significant (p&lt;0.0001)) demonstrated excellent statistical quality. Conclusions: This study indicated that QoL, PFS and OS are major drivers for therapy selection. Maximizing lifetime may be not an absolute goal and only desirable if no major loss of QoL occurs. Avoiding specific side effects was less relevant than maintaining QoL

Citation Format: Mattea Reinisch, Norbert Marschner, Thorsten Otto, Agnieszka Korfel, Clemens Stoffregen, Achim Wöckel. Patient preferences: Results of a German adaptive choice-based conjoint analysis study in patients on palliative treatment for advanced breast cancer (aBC) [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-17-08.